0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover726.40%IV-68.69%PremiumAug 30, 2024Expiry Date5.09Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6634Delta0.0720Gamma1.26Leverage Ratio-0.2956Theta-0.0009Rho-0.83Eff Leverage0.0025Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet